Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning

Award Number: R37CA262510
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/03/2022
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning - Project Summary/Abstract Glioblastoma is the most common cancer originating in the brain with ~12,000 new diagnoses per year in the U.S.A. and median survival about 18 months. A common dilemma for the patient and treatment team is that the clinical MRI one month after radiation therapy (RT) shows growth of unclear significance in up to 50% of patients. Patients with true progression (TP) of non-responding tumor continue to progress on serial MRIs and usually die within 9 months. TP is usually determined 6 or more months after completion of RT, often when it is too late to intervene. The mission of the National Cancer Institute is to improve survival of patients with cancer. Our goal, and an unmet need, is to identify glioblastoma patients with TP early during treatment and implement aggressive second-line therapy to improve survival. This proposal describes an innovative approach to identify early glioblastoma TP by improving neuroimaging and image processing on MRIdian, a new combination MRI and RT (MRI-RT) device from ViewRay, Inc where patients undergo MRI daily as part of their RT. Our preliminary data with MRIdian is the first to demonstrate daily glioblastoma growth on MRI in patients during RT. By developing physiologic MRI techniques on MRIdian (Aim 1), we seek to identify TP when there is growth during RT (Aim 2), and intensify RT to that TP (Aim 3/future). The most sensitive and specific commonly applied clinical MRI techniques for identifying TP after RT correlate with tumor physiology: diffusion (cellularity), perfusion (hypoxia), and spectroscopy (metabolism). These are collectively termed mpMRI. The hypothesis of aim 1 is that the academic-industrial partnership between Miami and ViewRay can develop mpMRI for daily measurements during RT on MRIdian. The hypothesis of aim 2 is that the images from daily mpMRI during MRI-RT in glioblastoma patients can be processed by machine learning and radiomics techniques to automatically detect glioblastoma growth and predict long-term outcome. Aim 3 then combines aims 1-2 to test a prospective workflow to intensify RT to TP when TP is first identified during RT based on mpMRI elucidated trends in tumor physiology, so called “physiologic adaptive RT” (PART). The PART workflow will be developed by Miami and Viewray and integrated into MRIdian. The advantage of using single platform MRIdian is that the PART workflow will be distributed by Viewray to the over 60 MRIdian centers. This easy clinical translation will permit us to proceed with multi-institutional trials of early RT dose escalation to improve survival of poorly responding glioblastomas.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $573,953 )
2026	2026	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	003	6	6/23/2026	NON-COMPETING CONTINUATION	$573,953
2026	2025	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	4	3/2/2026	NON-COMPETING CONTINUATION	-$291,453
2026	2025	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	002	4	6/9/2026	NON-COMPETING CONTINUATION	$0
2026	2025	MICHIGAN STATE UNIVERSITY	426 AUDITORIUM RD	EAST LANSING	MI	48824	INGHAM	USA	Cancer Detection and Diagnosis Research	001	5	3/2/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$291,453
														Subtotal = $573,953

Issue Date FY: 2025 ( Subtotal = $554,834 )
2025	2025	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	4	2/19/2025	NON-COMPETING CONTINUATION	$499,351
2025	2025	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	001	4	5/23/2025	NON-COMPETING CONTINUATION	$55,483
														Subtotal = $554,834

Issue Date FY: 2024 ( Subtotal = $527,094 )
2024	2024	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	3	2/5/2024	NON-COMPETING CONTINUATION	$499,351
2024	2024	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	001	3	4/17/2024	NON-COMPETING CONTINUATION	$27,743
														Subtotal = $527,094

Issue Date FY: 2023 ( Subtotal = $546,076 )
2023	2023	UNIVERSITY OF MIAMI	1400 NW 10TH AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	2	2/3/2023	NON-COMPETING CONTINUATION	$546,076
														Subtotal = $546,076

Issue Date FY: 2022 ( Subtotal = $604,883 )
2022	2022	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	1	3/3/2022	NEW	$604,883
														Subtotal = $604,883

Grand Total All Awards = $2,806,840

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning

Award Number: R37CA262510

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/03/2022

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer